Will a Democrat-led House only focus on pricing? Nope by Eric Sagonowsky Wednesday, November 7, 2018 Tuesday's midterm results already brought a dose of new promises to tackle drug prices. But that’s not the only headache pharma faces in the House.
BMS snags quick Empliciti combo nod in multiple myeloma by Carly Helfand Wednesday, November 7, 2018 Less than five months after posting positive top-line data, Bristol-Myers Squibb and AbbVie have scored a new combo win for Empliciti.
Celgene lines up for $600M Revlimid boost with lymphoma win by Carly Helfand Friday, November 2, 2018 Celgene’s Revlimid may have slipped in previously untreated follicular lymphoma. But in the second-line setting, the drug has a win.
Lilly, Merck and Pfizer lead pharma's 2018 stock growth: report by Eric Sagonowsky Wednesday, October 10, 2018 Several big drugmakers have posted big share price gains in the first nine months of the year, while other companies have seen only modest declines.
Celgene guns for expanded Otezla label in scalp psoriasis by Arlene Weintraub Tuesday, October 9, 2018 Expanding Otezla's market to scalp psoriasis could be challenging for Celgene, in light of hurdles such as mounting competition.
Agios crowns Jackie Fouse CEO to spearhead leukemia rollouts by Carly Helfand Wednesday, September 5, 2018 Jackie Fouse has been a prime CEO candidate since leaving Celgene, and it’s Agios that finally gets to claim her as its next skipper.
Juno investors eke out $24M deal in CAR-T trial death lawsuit by Eric Sagonowsky Wednesday, September 5, 2018 Juno didn't immediately report CAR-T trial deaths, investors argued in a lawsuit, and now the sides have inked a $24 million settlement.
Celgene veteran Fouse top pick for Gilead CEO: analyst by Arlene Weintraub Tuesday, July 31, 2018 RBC Capital Markets investors picked an oncology expert as their top candidate to replace Gilead CEO John Milligan.
